The 5-year cancer-specific survival (CSS) of stages I-II gastric cancer was 77.2% (95% CI 69.2–83.4) in patients with positive UCHL5 immunoexpression, compared to 59.0% (95% CI 41.3–73.0) in patients with negative UCHL5 immunoexpression. This evidence concerns the gene UCHL5 and gastric cancer.